Hematopoietic Stem Cell Transplant Utilization In Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis Of Statewide Claims Data

Introduction: In the era of novel therapies, the first and subsequent lines of therapies are rapidly evolving in the treatment of patients with Hodgkin lymphoma (HL) in order to optimize disease control and reduce long term health risks. Hematopoietic stem cell transplant (HSCT) is often used following treatment failure. While utilization of HSCT can be ascertained from transplant-specific registries, the treatment path for patients with relapsed/refractory HL leading up to HSCT is largely unknown. We developed an algorithm to define a cohort of commercially insured patients with HL from 2009-2013 in the Massachusetts All Payer Claims Database (MA APCD) who received HSCT. Further, we describe treatment characteristics of this cohort.